Efficacy and safety of single‐dose anti‐thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study
Pediatric Transplantation · 2024
DOI: 10.1111/petr.14713 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Luciana de Fatima Porini Custodio und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Kidney Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Background
This study aimed to compare the efficacy and safety of basiliximab (BAS) versus a single dose of anti‐thymocyte globulin (r‐ATG) induction therapy in pediatric kidney transplant recipients (KTRs).
Methods
This single‐center retrospective comparative cohort study included all pediatric KTRs from May 2013 to April 2018 and followed up to 12 months. In the first period, all recipients received BAS, while from May 2016, a single 3 mg/kg dose of r‐ATG was instituted. Maintenance therapy consisted of a calcineurin inhibitor plus prednisone plus azathioprine or mycophenolate.
Results
A total of 227 patients were included (BAS, n = 113; r‐ATG, n = 114). The main combination of immunosuppressive drugs was tacrolimus, prednisone, and azathioprine in both groups (87% vs. 88%, p = .718). Patients receiving r‐ATG showed superior survival‐free of the composite endpoint (acute rejection, graft loss, or death; 76% vs. 61%, p = .003; HR 2.08, 1.29–3.34, p = .003) and lower incidence of biopsy‐proven acute rejection (10% vs. 21%, p = .015). There was no difference in the overall incidence of CMV infection (33% vs. 37%, p = .457), PTLD (1% vs. 3%, p = .309), 30‐day hospital readmissions (24% vs. 23%, p = .847), and kidney function at 12 months (86 ± 29 vs. 84 ± 30 mL/min/1.73m 2 , p = .614).
Conclusions
These data suggest that induction therapy with a single 3 mg/kg dose of r‐ATG is associated with higher efficacy for preventing acute rejection and similar safety profile compared to BAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil.
- Nephrology Division, Universidade Federal de São Paulo, São Paulo, Brazil.
ORCID-Profile: Luciana de Fatima Porini Custodio, Suelen Bianca Stopa Martins, Laila Almeida Viana, Marina Pontello Cristelli, Lucio Requião-Moura, Charles Yea Zen Chow, Suzana Friedlander Del Nero Camargo, Monica Rika Nakamura, Renato Demarchi Foresto, Helio Tedesco-Silva, Jose Medina-Pestana
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Custodio, L. F. P., Martins, S. B. S., Viana, L. A., Cristelli, M. P., Requião-Moura, L., Chow, C. Y. Z., Camargo, S. F. D. N., Nakamura, M. R., Foresto, R. D., Tedesco-Silva, H., & Medina-Pestana, J. (2024). Efficacy and safety of single‐dose anti‐thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study. Pediatric Transplantation. https://doi.org/10.1111/petr.14713
Vancouver
Custodio LFP, Martins SBS, Viana LA, Cristelli MP, Requião-Moura L, Chow CYZ, et al. Efficacy and safety of single‐dose anti‐thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study. Pediatric Transplantation. 2024. doi:10.1111/petr.14713
BibTeX
@article{Custodio2024,
author = {Custodio, Luciana de Fatima Porini and Martins, Suelen Bianca Stopa and Viana, Laila Almeida and Cristelli, Marina Pontello and Requião-Moura, Lucio and Chow, Charles Yea Zen and Camargo, Suzana Friedlander Del Nero and Nakamura, Monica Rika and Foresto, Renato Demarchi and Tedesco-Silva, Helio and Medina-Pestana, Jose},
title = {Efficacy and safety of single‐dose anti‐thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study},
journal = {Pediatric Transplantation},
year = {2024},
doi = {10.1111/petr.14713}
}
EUVIMED